Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice (SFPRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04049188|
Recruitment Status : Recruiting
First Posted : August 8, 2019
Last Update Posted : January 23, 2020
|Condition or disease||Intervention/treatment||Phase|
|Cancer Metastatic||Radiation: Single-Fraction Palliative Radiation Therapy||Not Applicable|
Hospice care for terminally ill patients with metastatic cancer improves quality of life, pain control, and potentially also survival when patients are enrolled early.1-3 However, hospice programs are often seen by patients and their caregivers as the last resort after exhaustion of all effective treatment options. The need to revoke active treatment (for all hospice patients with cancer outside of the VA system) discourages hospice enrollment.
This study aims to understand and analyze barriers to access specifically for short course palliative radiation therapy in cancer patients enrolled in hospice.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Impact of Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice|
|Actual Study Start Date :||January 1, 2020|
|Estimated Primary Completion Date :||January 1, 2021|
|Estimated Study Completion Date :||December 31, 2021|
Experimental: Single-Fraction Palliative RT
Single-Fraction Palliative Radiation Therapy Adminstration
Radiation: Single-Fraction Palliative Radiation Therapy
All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
- Change in Opioid Use for Pain Management [ Time Frame: Through study completion, an average of 1 year ]Opioid Dosage (mg/day)
- Improved Quality of Life Measures [ Time Frame: During study completion ]Questionnaires using Herth Hope Index, Timed Up and Go, and Edmonton Symptom Assessment Scale
- Improved Activities of Daily Living [ Time Frame: During study completion ]Questionnaires using Hearth Hope Index, Timed Up and Go, and Edmonton Symptom Assessment Scale
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04049188
|Contact: Andy Kyler, BSN, MBAfirstname.lastname@example.org|
|Contact: Christa Nicholas||5036469565||Christa.Nicholas@carepartnersor.org|
|United States, Oregon|
|Hillsboro, Oregon, United States, 97006|
|Contact: Christa Nicholas 503-648-9565|
|Principal Investigator: Andy Kyler, BSN, MBA|